
Cytokinetics' Heart Drug Shows Promising Results in Recent Studies
A new drug from Cytokinetics, aficamten, showed improved exercise capacity over the common beta blocker metoprolol in a Phase 3 study for patients with hypertrophic cardiomyopathy, potentially accelerating its FDA approval and broader use.

